CASI PHARMACEUTICALS INC
NASDAQ: CASI (CASI Pharmaceuticals, Inc.)
Kemas kini terakhir: 2 hari lalu, 10:29AM2.31
-0.13 (-5.33%)
Penutupan Terdahulu | 2.44 |
Buka | 2.38 |
Jumlah Dagangan | 38,822 |
Purata Dagangan (3B) | 1,307,731 |
Modal Pasaran | 35,788,368 |
Harga / Jualan (P/S) | 1.23 |
Harga / Buku (P/B) | 11.21 |
Julat 52 Minggu | |
Tarikh Pendapatan | 14 Aug 2025 - 18 Aug 2025 |
Margin Keuntungan | -129.05% |
Margin Operasi (TTM) | -163.99% |
EPS Cair (TTM) | -2.54 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 83.00% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 1,196.16% |
Nisbah Semasa (MRQ) | 0.810 |
Aliran Tunai Operasi (OCF TTM) | -29.22 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -15.22 M |
Pulangan Atas Aset (ROA TTM) | -50.88% |
Pulangan Atas Ekuiti (ROE TTM) | -1,094.50% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Menurun |
Biotechnology (Global) | Bercampur | Menurun | |
Stok | CASI Pharmaceuticals, Inc. | Menurun | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | -2.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -2.0 |
Purata Bergerak Teknikal | -1.0 |
Osilator Teknikal | 2.0 |
Purata | -0.75 |
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Value |
% Dimiliki oleh Orang Dalam | 48.38% |
% Dimiliki oleh Institusi | 23.64% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Wellington Shields Capital Management, Llc | 30 Jun 2025 | 90,845 |
Adar1 Capital Management, Llc | 30 Jun 2025 | 44,120 |
Wellington Shields & Co., Llc | 30 Jun 2025 | 30,091 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
29 Aug 2025 | Pengumuman | CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results |
28 Aug 2025 | Pengumuman | CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025 |
04 Aug 2025 | Pengumuman | CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR) |
21 Jul 2025 | Pengumuman | CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |